Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Medtronic reports positive data from real-world MiniMed 530G study

Medtronic reports positive data from real-world MiniMed 530G study

13th February 2015

Medtronic has announced new data from a retrospective analysis of its MiniMed 530G insulin pump, based on real-world data from more than 20,000 users.

It was found that the pump's Threshold Suspend feature helped to reduce hypoglycaemia, especially at night, without significantly increasing hyperglycaemia. The findings mirrored those of the previous Aspire In-Home clinical study.

The MiniMed 530G system is the first and only system to offer this feature, which suspends insulin delivery for up to two hours when the sensor glucose value reaches a preset low level and the user is unable to respond to the corresponding alarm.

Overall hypoglycemia rates were reduced by 69 percent, with night-time cases reduced by 73 per cent.

Dr Francine Kaufman, chief medical officer and vice-president of global, clinical and medical affairs for Medtronic Diabetes, said: "The present analysis showed that when people with diabetes use the Threshold Suspend feature on the MiniMed 530G system in the real world, they experience the same reduction in hypoglycaemia that was observed in research trials."

The company greatly expanded the scope of its business last month by completing its takeover of Covidien, thus creating one of the largest medical technology firms in the world.ADNFCR-8000103-ID-801775275-ADNFCR

We currently have 9 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.